The DOI matches its Crossref record; 179 of the 179 references it cites were found in a registry or an index.
PI3K/AKT/mTOR signaling in gastric cancer: Epigenetics and beyond
Abstract
PI3K/AKT/mTOR pathway is one of the most important signaling pathways involved in normal cellular processes. Its aberrant activation modulates autophagy, epithelial-mesenchymal transition, apoptosis, chemoresistance, and metastasis in many human cancers. Emerging evidence demonstrates that some infections as well as epigenetic regulatory mechanisms can control PI3K/AKT/mTOR signaling pathway. In this review, we focused on the role of this pathway in gastric cancer development, prognosis, and metastasis, with an emphasis on epigenetic alterations including DNA methylation, histone modifications, and post-transcriptional modulations through non-coding RNAs fluctuations as well as H. pylori and Epstein-Barr virus infections. Finally, we reviewed different molecular targets and therapeutic agents in clinical trials as a potential strategy for gastric cancer treatment through the PI3K/AKT/mTOR pathway.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
11 retracted
Ueki, K., Fruman, D. A., Yballe, C. M., Fasshauer, M., Klein, J., Asano, T., Cantley, L. C., & Kahn, C. R. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m305602200 · Cited by 208
RetractedHuang, Y., Zhang, J., Hou, L., Wang, G., Liu, H., Zhang, R., Chen, X., & Zhu, J. (2017) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-017-0666-2 · Cited by 205
RetractedYang, P., Guo, J., Liu, Y., & Wu, X. (2014) · Bioscience Reports · doi:10.1042/bsr20140020 · Cited by 105
RetractedLi, C., Song, L., Zhang, Z., Bai, X., Cui, M., & Ma, L. (2016) · Oncotarget · doi:10.18632/oncotarget.11888 · Cited by 57
RetractedRETRACTED: MALAT1 promotes gastric adenocarcinoma through the MALAT1/miR-181a-5p/AKT3 axis
Lu, Z., Luo, T., Pang, T., Du, Z., Yin, X., Cui, H., Fang, G., & Xue, X. (2019) · Open Biology · doi:10.1098/rsob.190095 · Cited by 47
RetractedWei, T., Li, Y., Zhu, M., et al. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s216862 · Cited by 45
RetractedGuo, J., Yan, L., Duan, H., & Lu, Y. (2019) · Cancer Cell International · doi:10.1186/s12935-019-0879-x · Cited by 30
RetractedMa, F.-Z., An, K., & Li, Y. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s240965 · Cited by 24
RetractedLin, S., Wang, H., Yang, W., Wang, A., & Geng, C. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s220302 · Cited by 18
RetractedQin, L., Jia, Z., Xie, D., & Liu, Z. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.27344 · Cited by 17
Retracted
Cited by
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
Glaviano, A., Foo, A. S. C., Lam, H. Y., Yap, K. C. H., Jacot, W., Jones, R. H., Eng, H., Nair, M. G., Makvandi, P., Geoerger, B., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01827-6 · Cited by 2,138
Regulated cell death (RCD) in cancer: key pathways and targeted therapies
Peng, F., Liao, M., Qin, R., Zhu, S., Peng, C., Fu, L., Chen, Y., & Han, B. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01110-y · Cited by 832
Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer
Yu, L., Wei, J., & Liu, P. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.06.019 · Cited by 763
CCL5/CCR5 axis in human diseases and related treatments
Zeng, Z., Lan, T., Wei, Y., & Wei, X. (2022) · Genes & Diseases · doi:10.1016/j.gendis.2021.08.004 · Cited by 378
Metadata
- Authors
- Fattahi, S., Amjadi-Moheb, F., Tabaripour, R., Ashrafi, G. H., & Akhavan-Niaki, H.
- Venue
- Life Sciences
- Publisher
- Elsevier BV
- Published
- 2020-12
- Volume
- 262
- Pages
- 118513
- ISSN
- 0024-3205 (ISSN-L)
- OpenAlex
- W3090967605
- Cited by
- 400
- References
- 179
- FWCI
- 13.07
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.